Print this page for your doctor
CLINICAL TRIAL SUMMARY
MDACC Study No:
(clinicaltrials.gov NCT No:
A Pharmacokinetic and Pharmacodynamic Study to Evaluate the Safety and Feasibility of Continuous Infusion Nelarabine in Patients with Relapsed / Refractory Lymphoid Malignancies.
The goal of the clinical research study is to find the highest tolerable dose
of nelarabine when given as a continuous infusion to patients with a lymphoid
malignancy that has not responded to, or has come back after treatment with
chemotherapy. The safety of this drug will also be studied.
Phase of Study:
Only at MDACC
Estimated Length of Stay in Houston:
If hospitalized, length of hospitalization would be 5 days every 28 days.
Study Contact Information
For Clinical Trial Enrollment:
For General Questions about Clinical Trials:
800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)
Study Objectives / Outcomes
Study Status Information
Resources and Links
Return to List